Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (5666)	9/23/1998 11:21:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

09/23 10:31 RESEARCH ALERT - Drug stocks upgraded NEW YORK, Sept 23 (Reuters) - Southeast Research Partners said on Wednesday it raised its rating on many large drug companies to buy from neutral, believing the companies would continue to post double-digit earnings growth. -- Analysts Neil Sweig and Le Anne Zhao raised shares of Abbott Laboratories Inc. <ABT.N>, Bristol-Myers Squibb Co. <BMY.N>, American Home Products Corp. <AHP.N>, Pfizer <PFE.N>, Eli Lilly and Co. <LLY.N>, Johnson and Johnson <JNJ.N> and SmithKline Beecham Plc. <SBH.N> to buy from neutral. -- "We believe more and more money will move into these above average, consistently growing shares," Sweig said. -- Drug companies would stand apart from other multinational firms, posting solid earnings growth as other companies preannounce shortfalls, he said.